We estimate that Bristol-Myers Squibb's (NYSE:BMY) Cardiovascular drugs account for around 23% of the company's value, according to our estimates. Currently, the only drug in this segment is Eliquis. We expect solid growth for Eliquis in the near term, and believe that the sales will likely peak...
We estimate that Bristol-Myers Squibb's (NYSE:BMY) Cardiovascular drugs account for around 23% of the company's value, according to our estimates. Currently, the only drug in this segment is Eliquis. We expect solid growth for Eliquis in the near term, and believe that the sales will likely peak...
Share this Article
Recommended